Io­n­is hands off an an­ti­sense drug for kid­ney dis­ease, giv­ing all rights to Roche

Io­n­is is hand­ing Roche a drug on the cusp of Phase III.

Io­n­is an­nounced ear­ly Mon­day that Roche is in-li­cens­ing and ad­vanc­ing the an­ti­sense drug can­di­date known as IO­N­IS-FB-LRx in­to a Phase III clin­i­cal study. The drug is be­ing in­ves­ti­gat­ed for im­munoglob­u­lin A nephropa­thy (IgAN), a kid­ney dis­ease that can lead to re­nal fail­ure. The dis­ease is marked by im­munoglob­u­lin A buildup in the kid­neys, re­sult­ing in in­flam­ma­tion and ul­ti­mate­ly kid­ney fail­ure if left un­treat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER